Abstract: The present disclosure provides technologies for MYC inhibition, including, e.g. MYC fusion polypeptides and compositions comprising the same as well as methods of using the same. In particular, the present disclosure, among others, provides fusion polypeptides comprising a mutant MYC polypeptide and a repressor domain. In some embodiments, such fusion polypeptides and compositions comprising the same can be useful for inducing cancer cell apoptosis. Accordingly, in some embodiments, such fusion polypeptides and compositions comprising the same can be useful for cancer treatment.
Type:
Grant
Filed:
September 18, 2020
Date of Patent:
May 21, 2024
Assignee:
Helix Nanotechnologies Inc
Inventors:
Taylor Gill, Hannu Rajaniemi, Nikolai Eroshenko
Abstract: Disclosed herein are fusion polypeptides comprising: (i) a fragment antigen comprising an epitope of a target protein antigen; and (ii) a complement binding polypeptide. The disclosure also provides fusion polynucleotides (e.g., mRNA) encoding the same. Also disclosed herein are methods of making and using the fusion polypeptides and fusion polynucleotides of the present disclosure.
Type:
Grant
Filed:
March 3, 2022
Date of Patent:
October 3, 2023
Assignee:
Helix Nanotechnologies, Inc.
Inventors:
Kyle Backman, Nikhil Dhar, Nikolai Eroshenko, Taylor Gill, Kemo Jammeh, Marianna Keaveney, Justin Quinn, Hannu Rajaniemi, Everett Webster
Abstract: Disclosed herein is a modified ribonucleotide comprising a nucleoside comprising N4-acetylcytidine and/or 5-hydroxymethyluridine, and polyribonucleotides comprising the same. Also provided herein are compositions comprising a polyribonucleotide of the present disclosure and methods of making and using the same.